BCA
DNLI icon

Berman Capital Advisors’s Denali Therapeutics DNLI Stock Holding History

Berman Capital Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$0 Sell
5
-3
-38% -$169 ﹤0.01% 2094
2021
Q2 		$0 Buy
8
+1
+14% +$62 ﹤0.01% 1926
2021
Q1 		$0 Buy
7
+2
+40% +$134 ﹤0.01% 1790
2020
Q4 		$0 Buy
+5
New +$302 ﹤0.01% 1703
2020
Q3 		– Sell
-9
Closed – – 1631
2020
Q2 		$0 Buy
+9
New +$212 ﹤0.01% 1648

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Berman Capital Advisors's DNLI Position: Q3 2021 in Review

Berman Capital Advisors reduced its Denali Therapeutics (DNLI) stake by 38% in Q3 2021, selling an estimated $169 and leaving 5 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2094.

Berman Capital Advisors first reported a position in DNLI in Q2 2020 and has held it in 5 quarters since. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

  • Berman Capital Advisors held 5 shares of Denali Therapeutics worth $0 as of Q3 2021.
  • Berman Capital Advisors sold 3 Denali Therapeutics shares in Q3 2021, an estimated $169.
  • Denali Therapeutics made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #2094 holding.
  • Berman Capital Advisors first reported a position in Denali Therapeutics in Q2 2020 and has held it in 5 quarters since.
  • 214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.